Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support [3]

Journal of Clinical Oncology

Volumn 24, Issue 15, 2006, Pages 2392-2394

  Wolff, Antonio C ^a   Jones, Richard J ^a   Davidson, Nancy E ^a   Jeter, Stacie C ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

ADJUVANT THERAPY; BONE MARROW CELL; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG HALF LIFE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; INFECTION; LETTER; LEUKOCYTOSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; MASTECTOMY; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NOTE; RADIOTHERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTOSIS; MASTECTOMY; MYELOPROLIFERATIVE DISORDERS; NEUTROPENIA; RADIOTHERAPY; TAXOIDS;

EID: 33744818914     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.7174     Document Type: Letter

References (13)

1. Citron ML, Berry DA, Cirrincione C, et al: A randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup C9741 - CALGB 9741. J Clin Oncol 21:1431-1439, 2003
2. Pegfilgrastim package insert. Thousand Oaks, CA, Amgen Inc, September 15, 2005
3. Burstein HJ, Parker LM, Keshaviah A, et al: Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340-8347, 2005
4. Carlson RW, Anderson BO, Burstein HJ, et al: Breast Cancer. J Natl Compr Cane Netw 3:238-289, 2005
5. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
6. Kotto-Kome AC, Fox SE, Lu W, et al: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res 50:55-58, 2004
7. Zamboni WC: Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23:9S-14S, 2003
8. Crawford J: Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30:24-30, 2003
9. Brodsky RA, Bedi A, Jones RJ: Are growth factors leukemogenic? Leukemia 10:175-177, 1996
10. Papaldo P, Lopez M, Marolla P, et al: Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908-6918, 2005
11. Amgen press release: Amgen's fourth quarter 2004 adjusted earnings per share increased 26 percent to 58 cents; full year 2004 adjusted earnings per share increased 26 percent to $2.40. January 27, 2005 http://www.amgen.com/media/media_pr_detail.jsp?year=2005&releaseID=667302
12. Dear Oncologist Letter. Thousand Oaks, CA, Amgen Inc, October 2005
13. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: first and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005